EP2010215A4 - Verfahren und zusammensetzungen zur behandlung von morbus crohn - Google Patents
Verfahren und zusammensetzungen zur behandlung von morbus crohnInfo
- Publication number
- EP2010215A4 EP2010215A4 EP07755288A EP07755288A EP2010215A4 EP 2010215 A4 EP2010215 A4 EP 2010215A4 EP 07755288 A EP07755288 A EP 07755288A EP 07755288 A EP07755288 A EP 07755288A EP 2010215 A4 EP2010215 A4 EP 2010215A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- crohn
- disease
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13173241.4A EP2666480A3 (de) | 2006-04-10 | 2007-04-10 | Anwendungen und Zusammensetzungen zur Behandlung von Morbus Crohn |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79090906P | 2006-04-10 | 2006-04-10 | |
US80261606P | 2006-05-22 | 2006-05-22 | |
US80285806P | 2006-05-22 | 2006-05-22 | |
US80977006P | 2006-05-30 | 2006-05-30 | |
US81548906P | 2006-06-20 | 2006-06-20 | |
US84996706P | 2006-10-06 | 2006-10-06 | |
US90463707P | 2007-03-01 | 2007-03-01 | |
US90462607P | 2007-03-01 | 2007-03-01 | |
US91817407P | 2007-03-14 | 2007-03-14 | |
PCT/US2007/008962 WO2007120720A2 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of crohn's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13173241.4A Division EP2666480A3 (de) | 2006-04-10 | 2007-04-10 | Anwendungen und Zusammensetzungen zur Behandlung von Morbus Crohn |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2010215A2 EP2010215A2 (de) | 2009-01-07 |
EP2010215A4 true EP2010215A4 (de) | 2010-06-16 |
Family
ID=38610153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13173241.4A Withdrawn EP2666480A3 (de) | 2006-04-10 | 2007-04-10 | Anwendungen und Zusammensetzungen zur Behandlung von Morbus Crohn |
EP07755288A Withdrawn EP2010215A4 (de) | 2006-04-10 | 2007-04-10 | Verfahren und zusammensetzungen zur behandlung von morbus crohn |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13173241.4A Withdrawn EP2666480A3 (de) | 2006-04-10 | 2007-04-10 | Anwendungen und Zusammensetzungen zur Behandlung von Morbus Crohn |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP2666480A3 (de) |
CA (1) | CA2564435A1 (de) |
WO (1) | WO2007120720A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2758964A1 (en) | 2009-04-16 | 2010-10-21 | Abbott Biotherapeutics Corp. | Anti-tnf-.alpha. antibodies and their uses |
CN110170050A (zh) * | 2012-06-04 | 2019-08-27 | 高拉夫·阿格拉沃尔 | 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法 |
US10946091B2 (en) | 2012-06-04 | 2021-03-16 | Gaurav Agrawal | Compositions and methods for treating Crohn's disease and related conditions and infections |
JP6526025B2 (ja) | 2013-10-16 | 2019-06-05 | オンコバイオロジクス,インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3078675A1 (de) * | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind |
AU2017213775A1 (en) | 2016-02-03 | 2018-08-16 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (de) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US6451983B2 (en) | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2006
- 2006-10-30 CA CA002564435A patent/CA2564435A1/en not_active Abandoned
-
2007
- 2007-04-10 WO PCT/US2007/008962 patent/WO2007120720A2/en active Search and Examination
- 2007-04-10 EP EP13173241.4A patent/EP2666480A3/de not_active Withdrawn
- 2007-04-10 EP EP07755288A patent/EP2010215A4/de not_active Withdrawn
Non-Patent Citations (11)
Title |
---|
D'HAENS GEERT ET AL: "Advances in medical therapy for Crohn's disease.", CURRENT GASTROENTEROLOGY REPORTS DEC 2004 LNKD- PUBMED:15527680, vol. 6, no. 6, December 2004 (2004-12-01), pages 496 - 505, XP002580099, ISSN: 1522-8037 * |
HANAUER ET AL: "A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1053/J.GASTRO.2004.05.010, vol. 127, no. 1, 1 July 2004 (2004-07-01), pages 332, XP002580094, ISSN: 0016-5085 * |
HANAUER ET AL: "Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1053/J.GASTRO.2005.11.030, vol. 130, no. 2, 1 February 2006 (2006-02-01), pages 323 - 333, XP005284535, ISSN: 0016-5085 * |
HANAUER S B ET AL: "Rapid response to human anti-TNF monoclonal antibody adalimumab in patients with moderate to severely active Crohn's disease in the CLASSIC study", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 850, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S313 - S314, XP002580097, ISSN: 0002-9270 * |
PANACCIONE ET AL: "Advances in medical therapy of inflammatory bowel disease", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 6, 1 December 2005 (2005-12-01), pages 566 - 572, XP005134765, ISSN: 1471-4892 * |
PAPADAKIS KONSTANTINOS A ET AL: "Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 1, January 2005 (2005-01-01), pages 75 - 79, XP002580098, ISSN: 0002-9270 * |
SANDBORN WILLIAM ET AL: "Adalimumab, a human anti-TNF-alpha monoclonal antibody, induces clinical remission and response in patients with moderate to severely active Crohn's Disease irrespective of smoking status", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 99, no. 10, Suppl. S, 800, October 2004 (2004-10-01), & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, pages S259 - S260, XP002580096, ISSN: 0002-9270 * |
SANDBORN WILLIAM ET AL: "Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-a monoclonal antibody adalimumab (humira((R)))", GASTROENTEROLOGY, vol. 128, no. 4, Suppl. 2, 723, April 2005 (2005-04-01), & ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION/DIGEST IVE-DISEASE-WEEK; CHICAGO, IL, USA; MAY 14 -19, 2005, pages A111 - A112, XP002580095, ISSN: 0016-5085 * |
SANDBORN WILLIAM J ET AL: "An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC, US LNKD- DOI:10.1111/J.1572-0241.2004.40462.X, vol. 99, no. 10, 1 October 2004 (2004-10-01), pages 1984 - 1989, XP002477488, ISSN: 0002-9270 * |
SANDBORN WILLIAM J ET AL: "Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded, placebo-controlled study", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 843, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S311, XP002580092, ISSN: 0002-9270 * |
SANDBORN WILLIAM J ET AL: "Remission and clinical response induced and maintained in patients with active Crohn's disease treated for 1-year open-label with adalimumab", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 858, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S316 - S317, XP002580093, ISSN: 0002-9270 * |
Also Published As
Publication number | Publication date |
---|---|
EP2666480A3 (de) | 2014-07-30 |
WO2007120720A2 (en) | 2007-10-25 |
WO2007120720A3 (en) | 2007-12-21 |
EP2666480A2 (de) | 2013-11-27 |
EP2010215A2 (de) | 2009-01-07 |
CA2564435A1 (en) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2152318A4 (de) | Anwendungen und zusammensetzungen zur behandlung von schuppenflechten und morbus crohn | |
EP2069768A4 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
EP2297341A4 (de) | Verfahren und zusammensetzungen zur behandlung von morbus huntington | |
HK1134679A1 (zh) | 用於治療感染的組合物和方法 | |
EP1986665A4 (de) | Aus mikroalgen stammende zusammensetzungen zur verbesserung der gesundheit und des erscheinungsbilds der haut | |
GB0522311D0 (en) | Pharmaceutical compositions for the treatment of pain | |
EP2007385A4 (de) | Kardiovaskuläre zusammensetzung und ihre verwendung zur behandlung von morbus alzheimer | |
EP2201370A4 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes | |
IL197275A0 (en) | Pharmaceutical compositions of clonazepam and methods of use thereof | |
ZA200801706B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
EP2001503A4 (de) | Diagnose und behandlung von morbus alzheimer | |
ZA200800452B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
HK1131553A1 (zh) | 用於治療皮膚的美容組合物以及用於治療皮膚的方法 | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
ZA200800448B (en) | Methods and compositions for the prevention and treatment of inflammatory disease | |
EP2217238A4 (de) | Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie | |
ZA200708819B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
EP1954800A4 (de) | Zusammensetzung und verwendung von phyto-percolat zur behandlung von einer krankheit | |
EP2010215A4 (de) | Verfahren und zusammensetzungen zur behandlung von morbus crohn | |
GB0909297D0 (en) | Composition for the treatment of skin conditions | |
IL187405A0 (en) | Methods and compositions for the treatment of pain | |
EP1930017A4 (de) | Zusammensetzung zur prävention und behandlung von krankheiten von erwachsenen | |
EP1928247A4 (de) | Zusammensetzung und verwendung von phytopercolat zur behandlung von krankheiten | |
EP2231148A4 (de) | Pharmazeutische Zusammensetzung zur Behandlung und Vorbeugung von Herzerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081110 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1126673 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100520 |
|
17Q | First examination report despatched |
Effective date: 20110615 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20081110 Extension state: RS Payment date: 20081110 Extension state: MK Payment date: 20081110 Extension state: BA Payment date: 20081110 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBVIE BIOTECHNOLOGY LTD |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1126673 Country of ref document: HK |